| Issuer | % of Class | Filed |
|---|---|---|
|
Yarrow Bioscience, Inc.
13G/A
Amendment 3
YARW · 92941V407
|
0.6% |
8/13/2026
Event 8/13/2026
|
|
VYNE Therapeutics Inc.
13G/A
Amendment 2
VYNE · 92941V308
|
7/17/2026
Event 6/8/2026
|
|
|
VYNE Therapeutics Inc.
13G/A
Amendment 1
VYNE · 92941V308
|
7/14/2026
Event 7/13/2026
|
|
|
VYNE Therapeutics Inc.
13G
VYNE · 92941V308
|
5.6% |
6/15/2026
Event 6/8/2026
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.